144 related articles for article (PubMed ID: 30443037)
1. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
Mullard A
Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
[No Abstract] [Full Text] [Related]
2. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
3. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
4. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
[No Abstract] [Full Text] [Related]
5. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
6. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
7. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
8. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
9. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
Hwang TJ; Franklin JM; Kesselheim AS
Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
11. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
[TBL] [Abstract][Full Text] [Related]
12. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
[TBL] [Abstract][Full Text] [Related]
13. Diabetes medications and cardiovascular outcome trials: Lessons learned.
Patel KV; de Albuquerque Rocha N; McGuire DK
Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular safety of new type 2 diabetes drugs].
Hormigo Pozo A; Mancera Romero J
Semergen; 2014 Mar; 40(2):55-6. PubMed ID: 24655909
[No Abstract] [Full Text] [Related]
15. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
16. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
17. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
18. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
19. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
20. The FDA and hypoglycemic drugs.
Davidson JK
JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764
[No Abstract] [Full Text] [Related]
[Next] [New Search]